Oil prices could rise further if U.S.-Iran talks remain thorny, Citi said, though inventory drawdowns, Strategic Petroleum Reserve releases, reduced Chinese imports, weaker demand and periodic signs... ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Cencora, Inc. ("Cencora†or the "Companyâ€) (NYSE: COR) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CENCORA, INC. (COR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 6, 2026, Cencora released its second quarter 2026 financial results, inclu. ...

INVESTOR DEADLINE ALERT: Grocery Outlet Holding (GO) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Accessibility Statement Skip Navigation Did you buy GO securities between August 5, 2025, and March 4, 2026? Why did Grocery Outlet's Stock Drop? Affected GO Investor Summary RADNOR, Pa., May 8, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action l ...

公司动态 - Frank R Cruz律师事务所宣布对Graphic Packaging Holding Company展开调查 调查涉及公司可能违反联邦证券法的行为 并代表可能因此蒙受损失的投资者[1] - 调查与2025年5月1日发生的事件相关[1]

核心观点 - argenx公司宣布其核心产品VYVGART及VYVGART Hytrulo获得美国FDA扩大标签批准，用于治疗所有血清分型的成人全身型重症肌无力患者，成为该领域首个且唯一覆盖所有血清分型的疗法[1][4] 监管批准与市场地位 - 美国FDA批准了VYVGART的补充生物制品许可申请，将其适应症扩大至覆盖所有血清分型的成人gMG患者，包括抗AChR抗体阳性、抗MuSK抗体阳性、抗LRP4抗体阳性和三重血清阴性[1] - 此次批准使VYVGART和VYVGART Hytrulo成为首个且唯一获批用于所有血清分型成人gMG患者的治疗方法[4] - 此次批准标志着argenx实现了迄今为止最广泛的MG产品标签覆盖[4] 临床试验数据与疗效 - 批准基于III期ADAPT SERON研究的数据，该研究是迄今为止针对无抗乙酰胆碱受体抗体可检测的gMG患者规模最大的研究，覆盖抗MuSK抗体阳性、抗LRP4抗体阳性和三重血清阴性三种血清分型[2] - 研究总体人群显示，接受VYVGART治疗的患者gMG症状得到快速、显著且持续的改善，包括言语、视力、身体功能和吞咽等[2] - 研究达到了主要终点，与安慰剂相比，接受VYVGART治疗的患者在第4周时MG-ADL总分实现了统计学上的显著改善[5] - 在研究总体人群中，接受VYVGART治疗的患者在第4周时MG-ADL总分较基线平均改善3.35分，具有临床意义[5] - 在所有研究的血清分型中，患者均显示出疾病活动的临床意义改善[5] - VYVGART在所有血清分型中耐受性良好，其安全性与在抗AChR抗体阳性gMG患者中已确立的安全性特征一致[2][5] 疾病背景与未满足需求 - 全身型重症肌无力是一种罕见的慢性神经肌肉自身免疫性疾病，约20%的gMG患者没有可检测到的抗AChR抗体[9] - 在无抗AChR抗体可检测的患者中，抗MuSK抗体阳性约占1-10%，抗LRP4抗体阳性约占1-5%，约10%的患者为三重血清阴性[9] - 历史上，三重血清阴性患者常被排除在研究之外，与有可检测自身抗体的患者相比，疾病负担更重，医疗需求未得到满足[9] - 此次批准意味着所有成人gMG患者，无论血清分型如何，现在都能受益于VYVGART的快速起效、持续的疾病控制和良好的安全性[3] 产品管线与未来发展 - argenx近期宣布了VYVGART Hytrulo用于眼肌型MG的ADAPT OCULUS研究的积极顶线结果[6] - 公司仍致力于推进VYVGART用于所有MG患者的开发，包括ADAPT Jr研究中的儿童gMG患者群体[6] - VYVGART目前有三种给药方案可供患者选择，包括使用预充式注射器进行VYVGART Hytrulo自我注射[7] - VYVGART是一种首创的人IgG1抗体片段，可与新生儿Fc受体结合，从而减少循环中的IgG自身抗体[25] - VYVGART Hytrulo是efgartigimod alfa与重组人透明质酸酶PH20的皮下注射组合[25] 商业化与患者支持 - argenx的患者支持项目“My VYVGART Path”可帮助患者和医疗保健提供者获取药物，资源包括疾病和产品教育、获取支持和福利验证，以及为符合条件的患者提供经济援助计划[8]

The fund I'm bringing you today does something that none among those analyzed has done. Yet it's something that in emerging markets in my opinion can bring value: it has made a selection. That's right, thisFinancial Serenity is a financial analysis and quantitative research column with a particular focus on the asset management sector. It is actively managed by Tommaso Scarpellini, a seasoned financial researcher and data analyst with proven experience in banking and financial analytics platforms. This init ...

REGINA, Saskatchewan, May 08, 2026 (GLOBE NEWSWIRE) -- Information Services Corporation (TSX:ISC) (ISC or the Company) advises that it will release its financial results for the three months ended March 31, 2026 on Friday, May 15, 2026 after market close. ISC’s Unaudited Condensed Consolidated Interim Financial Statements and Notes and Management’s Discussion and Analysis for the three months ended March 31, 2026 will be available on SEDAR+ at sedarplus.ca and our website at investors.isc.ca. An investor co ...

Source Energy Services Reports 2026 AGM ResultsBack to the NewsroomSource Energy Services Reports 2026 AGM ResultsCALGARY, AB / ACCESS Newswire/ May 8, 2026 / (TSX:SHLE)Source Energy Services Ltd. ("Source" or the "Company") reports results from its annual meeting shareholder held May 8, 2026.2026 AGM Voting ResultsElection of DirectorsAll of the proposed nominees were elected to Source's board of directors (the "Board") by Shareholders present or represented by proxy at the Meeting. The voting results are ...

Rosen Law Firm Urges Graphic Packaging Holding Company (NYSE: GPK) Stockholders to Contact the Firm for Information About Their Rights May 8, 2026 5:15 PM Eastern Daylight Time Rosen Law Firm Urges Graphic Packaging Holding Company (NYSE: GPK) Stockholders to Contact the Firm for Information About Their Rights Share NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Graphic Packaging Holding Company (NYSE: G ...

分析师评级与目标价调整 - CIBC将Enerflex的目标股价从25.00美元上调至28.00美元 此举反映了对公司积极的投资展望 [1] - 发布评级调整时 公司股价为27.59美元 [1] 2026年第一季度财务业绩 - 季度营收达到5.84亿美元 较去年同期的5.52亿美元实现增长 但较上一季度的6.27亿美元有所下降 [2] - 营收增长主要由其Engineered Systems产品线驱动 [2] - 调整后EBITDA达到1.37亿美元 [3] - 资本回报率创下17.3%的历史记录 表明公司资本使用效率高 [3] 运营与财务健康状况 - 公司两大主要业务板块的合并积压订单达到13亿美元 显示出强劲的运营能见度 [4] - 银行调整后的净债务与EBITDA比率为0.9倍 显示财务健康且债务风险低 [4]